Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Bittar, Cíntia ^a   Jardim, Ana C G ^a   Yamasaki, Lilian H T ^a   de Queiróz, Artur T L ^b   Carareto, Claudia M A ^a   Pinho, João R R ^b,c   de Carvalho Mello, Isabel M V ^d   Rahal, Paula ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^d INSTITUTO BUTANTAN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; CONTIG; INTERFERON; NONSTRUCTURAL PROTEIN 5A; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTIG MAPPING; CONTROLLED STUDY; DNA PURIFICATION; DNA SYNTHESIS; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC DISTANCE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PROTEIN ANALYSIS; RNA ISOLATION; SEQUENCE ANALYSIS; STOP CODON; TREATMENT RESPONSE; VIRUS GENOME; VIRUS ISOLATION; VIRUS LOAD; AMINO ACID SEQUENCE; CLASSIFICATION; CLUSTER ANALYSIS; DNA SEQUENCE; GENETICS; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; POINT MUTATION; TREATMENT OUTCOME; VIROLOGY;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POINT MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 77649278552     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-36     Document Type: Article

References (57)

1. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005, 436(7053):946-952. 10.1038/nature04079, 16107834.
2. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007, 13(17):2436-2441.
3. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244(4902):359-362. 10.1126/science.2523562, 2523562.
4. Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992, 66(5):3225-3229. 241092, 1313927.
5. Silva LK, Parana R, Souza SP, Berby F, Kay A, Trepo C, Santana N, Cotrim H, Lyra LG, Reis MG. Hepatitis C virus genotypes in a northeastern area of Brazil. Am J Trop Med Hyg 2000, 62(2):257-260.
6. Campiotto S, Pinho JR, Carrilho FJ, Da Silva LC, Souto FJ, Spinelli V, Pereira LM, Coelho HS, Silva AO, Fonseca JC, et al. Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005, 38(1):41-49. 10.1590/S0100-879X2005000100007, 15665987.
7. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995, 15(1):41-63. 10.1055/s-2007-1007262, 7597443.
8. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, Holland JJ. Basic concepts in RNA virus evolution. Faseb J 1996, 10(8):859-864.
9. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin Liver Dis 1999, 3(4):693-716. 10.1016/S1089-3261(05)70234-8, 11291246.
10. Forns X, Purcell RH, Bukh J. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol 1999, 7(10):402-410. 10.1016/S0966-842X(99)01590-5, 10498948.
11. Farci P, Strazzera R, Alter HJ, Farci S, Degioannis D, Coiana A, Peddis G, Usai F, Serra G, Chessa L, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002, 99(5):3081-3086. 10.1073/pnas.052712599, 122476, 11880647.
12. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C, Payan C, Pivert A, Goudeau A, Lunel-Fabiani F. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J Gastroenterol 2007, 13(17):2416-2426.
13. Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005, 436(7053):939-945. 10.1038/nature04078, 16107833.
14. Eigen M, Biebricher C. Sequence space and quasispecies distribution. 1988, 3. Boca Raton, FL: CRC Press.
15. Eigen M. Viral quasispecies. Sci Am 1993, 269(1):42-49. 10.1038/scientificamerican0793-42, 8337597.
16. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995, 267(5197):483-489. 10.1126/science.7824947, 7824947.
17. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996, 334(2):77-81. 10.1056/NEJM199601113340203, 8531962.
18. Chayama K, Tsubota A, Kobayashi M, Okamoto K, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 1997, 25(3):745-749. 10.1002/hep.510250342, 9049229.
19. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, Kobayashi M, Kobayashi M, et al. Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA. Intern Med 1999, 38(6):461-466. 10.2169/internalmedicine.38.461, 10411349.
20. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997, 25(3):750-753. 10.1002/hep.510250343, 9049230.
21. Nakano I, Fukuda Y, Katano Y, Nakano S, Kumada T, Hayakawa T. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?. J Hepatol 1999, 30(6):1014-1022. 10.1016/S0168-8278(99)80254-2, 10406178.
22. Berg T, Mas Marques A, Hohne M, Wiedenmann B, Hopf U, Schreier E. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 2000, 32(6):1386-1395. 10.1053/jhep.2000.20527, 11093746.
23. Duverlie G, Khorsi H, Castelain S, Jaillon O, Izopet J, Lunel F, Eb F, Penin F, Wychowski C. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. J Gen Virol 1998, 79(Pt 6):1373-1381.
24. Sarrazin C, Berg T, Lee JH, Ruster B, Kronenberger B, Roth WK, Zeuzem S. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. J Infect Dis 2000, 181(2):432-441. 10.1086/315263, 10669323.
25. Squadrito G, Orlando ME, Cacciola I, Rumi MG, Artini M, Picciotto A, Loiacono O, Siciliano R, Levrero M, Raimondo G. Long-term response to interferon alpha is unrelated to "interferon sensitivity determining region" variability in patients with chronic hepatitis C virus-1b infection. J Hepatol 1999, 30(6):1023-1027. 10.1016/S0168-8278(99)80255-4, 10406179.
26. Zeuzem S, Lee JH, Roth WK. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa. Hepatology 1997, 25(3):740-744. 10.1002/hep.510250341, 9049228.
27. Chung RT, Monto A, Dienstag JL, Kaplan LM. Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus. J Med Virol 1999, 58(4):353-358. 10.1002/(SICI)1096-9071(199908)58:4<353::AID-JMV6>3.0.CO;2-C, 10421401.
28. Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL, Gretch DR. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000, 74(19):9028-9038. 10.1128/JVI.74.19.9028-9038.2000, 102099, 10982347.
29. Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci 2002, 47(6):1195-1205. 10.1023/A:1015349924116, 12064791.
30. Pascu M, Martus P, Hohne M, Wiedenmann B, Hopf U, Schreier E, Berg T. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004, 53(9):1345-1351. 10.1136/gut.2003.031336, 1774214, 15306598.
31. Domingo E, Holland JJ. Mutation rates and rapid evolution of RNA viruses. The Evolutionary Biology of Viruses 1994, 161-184. Edited by Raven. New York.
32. Domingo E, Holland JJ, Ahlquist P. RNA Genetics. 1988, Boca Raton, FL: CRC Press.
33. Domingo E, Holland JJ, Biebricher C, Eigen M. Quasispecies: the concept and the word. Molecular Evolution of the Viruses 1995, 171-180. Cambridge: Cambridge Univ. Press, Gibbs A, Calisher C, García-Arenal F.
34. Domingo E, Martinez-Salas E, Sobrino F, de la Torre JC, Portela A, Ortin J, Lopez-Galindez C, Perez-Brena P, Villanueva N, Najera R, et al. The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene 1985, 40(1):1-8. 10.1016/0378-1119(85)90017-4, 3912262.
35. Gebauer F, de la Torre JC, Gomes I, Mateu MG, Barahona H, Tiraboschi B, Bergmann I, de Mello PA, Domingo E. Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J Virol 1988, 62(6):2041-2049. 253289, 2835508.
36. Holland JJ. Continuum of change in RNA virus genomes. Concepts in Viral Pathogenesis 1984, 137-143. New York: Springer-Verlag, Notkins AL, Oldstone MBA.
37. Holland J, de la Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992, (176):1-20.
38. Temin HM. Is HIV unique or merely different?. J Acquir Immune Defic Syndr 1989, 2(1):1-9.
39. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373(6510):117-122. 10.1038/373117a0, 7529365.
40. Jardim AC, Yamasaki LH, de Queiroz AT, Bittar C, Pinho JR, Carareto CM, Rahal P, Mello IM. Quasispecies of hepatitis C virus genotype 1 and treatment outcome with Peginterferon and Ribavirin. Infect Genet Evol 2009, 9(4):689-698. 10.1016/j.meegid.2008.11.001, 19063998.
41. Craig S, Thu HM, Lowry K, Wang XF, Holmes EC, Aaskov J. Diverse dengue type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol 2003, 77(7):4463-4467. 10.1128/JVI.77.7.4463-4467.2003, 150639, 12634407.
42. Aaskov J, Buzacott K, Thu HM, Lowry K, Holmes EC. Long-term transmission of defective RNA viruses in humans and Aedes mosquitoes. Science 2006, 311(5758):236-238. 10.1126/science.1115030, 16410525.
43. Sugiyama K, Suzuki K, Nakazawa T, Funami K, Hishiki T, Ogawa K, Saito S, Shimotohno KW, Suzuki T, Shimizu Y, et al. Genetic analysis of hepatitis C virus with defective genome and its infectivity in vitro. J Virol 2009, 83(13):6922-6928. 10.1128/JVI.02674-08, 2698526, 19369330.
44. Tong X, Malcolm BA. Trans-complementation of HCV replication by non-structural protein 5A. Virus Res 2006, 115(2):122-130. 10.1016/j.virusres.2005.07.012, 16146661.
45. Appel N, Herian U, Bartenschlager R. Efficient rescue of hepatitis C virus RNA replication by trans-complementation with nonstructural protein 5A. J Virol 2005, 79(2):896-909. 10.1128/JVI.79.2.896-909.2005, 538567, 15613318.
46. BioMol - Electropherogram quality analysis. , http://www.biomol.unb.br/phph/
47. Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998, 8(3):186-194.
48. Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998, 8(3):175-185.
49. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 1997, 25(24):4876-4882. 10.1093/nar/25.24.4876, 147148, 9396791.
50. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symposium Series 1999, 41:95-98.
51. Marucci EA, Zafalon GF, Jardim AC, Yamasaki LH, Bittar C, Rahal P, Machado JM. Routine libraries for pattern recognition in quasispecies. Genet Mol Res 2008, 7(3):970-981. 10.4238/vol7-3X-Meeting013, 18949714.
52. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0. Mol Biol Evol 2007, 24(8):1596-1599. 10.1093/molbev/msm092, 17488738.
53. Korber B. HIV Signature and Sequence Variation Analysis. Computational Analysis of HIV Molecular Sequences. 2000, Dordrecht, Netherlands: Kluwer Academic Publishers.
54. HCV sequence database. , http://www.hiv.lanl.gov
55. Swofford DL. PAUP*Phylogenetic Analysis Using Parsimony (*and Others Methods). 2002, Sunderland, Massachusetts.
56. Posada D, Crandall KA. MODELTEST: testing the model of DNA substitution. Bioinformatics 1998, 14(9):817-818. 10.1093/bioinformatics/14.9.817, 9918953.
57. McCormack GP, Clewley JP. The application of molecular phylogenetics to the analysis of viral genome diversity and evolution. Rev Med Virol 2002, 12(4):221-238. 10.1002/rmv.355, 12125014.